Language
The week in pharma: action, reaction and insight

Blog

HomeHome / Blog / The week in pharma: action, reaction and insight
search

Mar 08, 2023

Texas

Aug 14, 2023

Egyptian propolis extract for functionalization of cellulose nanofiber/poly(vinyl alcohol) porous hydrogel along with characterization and biological applications

Aug 17, 2023

New Hydrogel Solar Evaporator Resembles Janus Structure

Sep 11, 2023

The effect of Alnus incana (L.) Moench extracts in ameliorating iron overload

Sep 05, 2023

New molecular structure based models for estimation of the CO2 solubility in different choline chloride

Send your inquiry
SUBMIT

Apr 13, 2023

The week in pharma: action, reaction and insight

14-05-2023Comments (0)Print 01-03-2023 15-12-2022 11-03-2022 02-03-2022

14-05-2023Comments (0)Print

01-03-2023

15-12-2022

11-03-2022

02-03-2022

04-02-2020

06-06-2023

06-06-2023

05-06-2023

By Barbara Obstoj-Cardwell. Editor

US biopharma firm Insmed held a meeting with analysts last Monday, when it unveiled a new research platform in the area of Duchenne muscular dystrophy and other diseases. Two M&A deals featured last week, first with US biotech major Gilead Sciences revealing the acquisition of XinThera, which will expand its early-stage oncology and inflammatory diseases portfolio. Also, Swedish Orphan Biovitrum (Sobi) announced…

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

• All the news that moves the needle in pharma and biotech.• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. • Receive The Pharma Letter daily news bulletin, free forever.

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.• Daily roundup of key events in pharma and biotech.• Monthly in-depth briefings on Boardroom appointments and M&A news.• Choose from a cost-effective annual package or a flexible monthly subscription.

BiotechnologyCompanies, mergers and acquisitionsCTI BioPharmaFocus OnGilead SciencesHematologyInflammatory diseasesInsmedMusculoskeletalOncologyRare diseasesReata PharmaceuticalsRegulationSkyclarysSwedish Orphan BiovitrumUS FDAVonjoXinThera

By Barbara Obstoj-Cardwell. Editor